Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery.
Why are we doing the BRIDGE Study?
- The BRIDGE study aims to provide definitive evidence about the pros and cons of bridging anticoagulation and will establish an evidence-based standard-of-care.
- This research study will determine the possible benefits and harms of bridging anticoagulation and will inform doctors about the best way to care for patients.
- There has never been a controlled study to determine whether switching patients from warfarin to heparin around the time of surgeries and procedures (“bridging anticoagulation”), or simply stopping warfarin is the best strategy to prevent arterial thrombotic events (ATEs) or clotting.
- Funded by the National Heart, Lung, and Blood Institute (NHLBI): [NCT00786474]
What are the study objectives?
- To compare the efficacy of bridging anticoagulation (therapeutic-dose LMWH) with no bridging anticoagulation (placebo) on the rate of arterial thromboembolic events (ATE)
- To compare the safety of bridging anticoagulation with no bridging anticoagulation on the rate of major bleeding
How to Participate
The Duke Clinical Research Institute is currently recruiting sites with access to perioperative and coumadin clinics that can enroll two patients per month, which is critical for us to meet the study goal of 3,626 patients by the end of March 2014.
We invite you to join our current sites participating in this important clinical trial.
Click here to complete our Site Survey!
Visit our study home site at https://bridge.dcri.duke.edu/
If you would like more information about the BRIDGE study, please contact:
Patty Darragh, Lead CRA